Xalkori for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma, approved by FDA
The Food and Drug Administration ( FDA ) has approved Xalkori ( Crizotinib ) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma ( ALCL ) that is ALK-positive.
The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Efficacy was evaluated in Study ADVL0912, a multicenter, single-arm, open-label trial in patients 1 to less than or equal to 21 years of age that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least one systemic treatment.
Patients received crizotinib 280 mg/m2 ( 20 patients ) or 165 mg/m2 ( 6 patients ) orally twice daily until disease progression or unacceptable toxicity.
Patients were permitted to discontinue Xalkori to undergo hematopoietic stem cell transplantation.
Efficacy was based on objective response rate ( ORR ) and duration of response as assessed by an independent review committee.
The ORR in the 26 patients was 88% ( 95% CI: 71, 96 ), with a complete remission rate of 81%. Of the 23 patients who achieved a response, 39% maintained response for at least 6 months, and 22% maintained response for at least 12 months.
Ocular toxicity ( grade 1 or 2 visual disorders ) occurred in 65% of patients with ALCL, gastrointestinal toxicity occurred in 92%, and serious adverse reactions occurred in 35%, most often from neutropenia and infection.
The most common adverse reactions ( greater than or equal to 35% ), excluding laboratory abnormalities, were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, pyrexia, abdominal pain, cough, and pruritus.
Grade 3-4 laboratory abnormalities ( greater than or equal to 15% ) were neutropenia, lymphopenia, and thrombocytopenia.
The recommended Xalkori dosage for systemic anaplastic large cell lymphoma is 280 mg/m2 orally twice daily based on body surface area.
Antiemetics are recommended prior to and during treatment with Xalkori in patients with anaplastic large cell lymphoma.
Due to the risk of visual loss, ophthalmologic evaluations are recommended at baseline and serially thereafter, coupled with monthly assessments of visual acuity and visual symptoms.( Xagena )
Source: FDA, 2021
Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at...
Rinvoq for the treatment of psoriatic arthritis and ankylosing spondylitis, approved by European Commission
The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...
Opdivo in combination with Cabometyx as first-line treatment for patients with advanced renal cell carcinoma, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Opdivo ( Nivolumab ) 240 mg injection for intravenous...
Bavencio for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, approved by European Commission
The European Commission ( EC ) has approved Bavencio ( Avelumab ) as monotherapy for the first-line maintenance treatment of...
EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus...
Keytruda as first-line treatment in adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer, approved by European Commission
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...
FDA has approved Breyanzi ( Lisocabtagene maraleucel ), a new CAR T cell therapy for adults with relapsed or refractory large B-cell lymphoma
The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric...
FDA has approved Tepmetko, an oral MET inhibitor for patients with metastatic non-small cell lung cancer and METex14 skipping alterations
The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...
CHRYSALIS study: Amivantamab has shown clinical activity and durable responses in patients with metastatic or unresectable non-small cell lung cancer and EGFR exon 20 insertion mutations
New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...